T-Bird Pharma to Receive Funding from Canadian Government
T-Bird Pharma Inc. (TSXV:TPI) announced that it will be receiving funding from the National Research Council of Canada-IRAP. The money will go towards research and development work regarding the company’s strains of medical cannabis.
As quoted in the press release:
Specifically, the funding will be used to characterize strains and utilize the data generated to assist in: identifying strains with specific compositions of cannabinoids, develop new strains using the Company’s range of genetic material and to ultimately match these strains with patients’ needs.
Dr. Bin Huang, CEO of T-Bird, commented:
We are excited to have received both the financial and technical support of the NRC-IRAP and look forward to working with them. Collaborating with both industry and academic research partners is a key part of our strategy to become the preeminent LP providing patients with pharmaceutical grade medical marijuana.